Advanced search
Publication Cover
Expert Review of Vaccines Volume 7, 2008 - Issue 1
Submit an article Journal homepage
384
Views
39
CrossRef citations to date
0
Altmetric
Perspective

Oral adenoviral-based vaccines: historical perspective and future opportunity

Sean N Tucker Vaxart, Inc., 600 Townsend St, Suite 120E, San Francisco, CA 94103, USA. [email protected]
,
Debora W Tingley Vaxart, Inc. 600 Townsend St, Suite 120E, San Francisco, CA 94103, USA. [email protected]
&
Ciaran D Scallan Vaxart, Inc. 600 Townsend St, Suite 120E, San Francisco, CA 94103, USA. [email protected]
Pages 25-31 | Published online: 09 Jan 2014

References

  • Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther.16(2), 149–156 (2005).
  • Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J. Virol.81(8), 4145–4157 (2007).
  • Hilleman MR, Werner JH. Recovery of new agent from patients with acute respiratory illness. Proc. Soc. Exp. Biol. Med.85, 183–188 (1954).
  • Russell KL, Hawksworth AW, Ryan MA et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. Vaccine24(15), 2835–2842 (2006).
  • Buescher EL. Respiratory disease and the adenoviruses. Med. Clin. North Am.51(3), 769–779 (1967).
  • Top FH Jr, Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J. Infect. Dis.124(2), 155–160 (1971).
  • Top FH Jr, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am. J. Epidemiol.94(2), 142–146 (1971).
  • Top FH Jr, Grossman RA, Bartelloni PJ et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J. Infect. Dis.124(2), 148–154 (1971).
  • Dudding BA, Bartelloni PJ, Scott RM, Top FH Jr, Russell PK, Buescher EL. Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infect. Immun.5(3), 295–299 (1972).
  • Schwartz AR, Togo Y, Hornick RB. Clinical evaluation of live, oral types 1, 2–5 adenovirus vaccines. Am. Rev. Respir. Dis.109(2), 233–239 (1974).
  • Scott RM, Dudding BA, Romano SV, Russell PK. Enteric immunization with live adenovirus type 21 vaccine. II. Systemic and local immune responses following immunization. Infect. Immun.5(3), 300–304 (1972).
  • Mueller RE, Muldoon RL, Jackson GG. Communicability of enteric liver adenovirus type 4 vaccine in families. J. Infect. Dis.119(1), 60–66 (1969).
  • Stanley ED, Jackson GG. Spread of enteric live adenovirus type 4 vaccine in married couples. J. Infect. Dis.119(1), 51–59 (1969).
  • Pavlov DN, Van Zyl WB, Kruger M, Blignaut L, Grabow WO, Ehlers MM. Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa. Diagn. Microbiol. Infect. Dis.54(1), 23–30 (2006).
  • Frey J. Biological safety concepts of genetically modified live bacterial vaccines. Vaccine25(30), 5598–5605 (2007).
  • Catelli E, Cecchinato M, Savage CE, Jones RC, Naylor CJ. Demonstration of loss of attenuation and extended field persistence of a live avian metapneumovirus vaccine. Vaccine24(42–43), 6476–6482 (2006).
  • Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol. Rev.28, 3–26 (2006).
  • Howell MR, Nang RN, Gaydos CA, Gaydos JC. Prevention of adenoviral acute respiratory disease in Army recruits: cost–effectiveness of a military vaccination policy. Am. J. Prev. Med.14(3), 168–175 (1998).
  • Davis AR, Kostek B, Mason BB et al. Expression of hepatitis B surface antigen with a recombinant adenovirus. Proc. Natl Acad. Sci. USA82(22), 7560–7564 (1985).
  • Morin JE, Lubeck MD, Barton JE, Conley AJ, Davis AR, Hung PP. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Proc. Natl Acad. Sci. USA84(13), 4626–4630 (1987).
  • Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med.55, 355–372 (2004).
  • Tang M, Harp JA, Wesley RD. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Arch. Virol.147(11), 2125–2141 (2002).
  • Lin SW, Cun AS, Harris-McCoy K, Ertl HC. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine25(12), 2187–2193 (2007).
  • Lubeck MD, Davis AR, Chengalvala M et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl Acad. Sci. USA86(17), 6763–6767 (1989).
  • Mutwiri G, Bateman C, Baca-Estrada ME, Snider M, Griebel P. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector. Vaccine19(9–10), 1284–1293 (2000).
  • Shibolet O, Podolsky DK. TLRs in the gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am. J. Physiol. Gastrointest. Liver. Physiol.292(6), G1469–G1473 (2007).
  • CroyleMA, Stone M, Amidon GL, Roessler BJ. In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine.Gene Ther.5(5), 645–654 (1998).
  • Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine25(11), 2074–2084 (2007).
  • Mercier GT, Campbell JA, Chappell JD, Stehle T, Dermody TS, Barry MA. A chimeric adenovirus vector encoding reovirus attachment protein σ1 targets cells expressing junctional adhesion molecule 1. Proc. Natl Acad. Sci. USA101(16), 6188–6193 (2004).
  • Tucker S, Tingley D, Scallan C. Dramatic improvement in oral gene-based vaccination by chimeric adenoviral vectors. Presented at: Modern Vaccines, Adjuvant, and Delivery Systems. Royal Society of Medicine, London, England, UK, 12–14 September 2006.
  • Knopf HL, Blacklow NR, Glassman MI, Cline WL, Wong VG. Antibody in tears following intranasal vaccination with inactivated virus. II. Enhancement of tear antibody production by the use of polyinosinic: polycytidilic acid (poly I:C). Invest. Ophthalmol.10(10), 750–759 (1971).
  • Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol.79(5), 2910–2919 (2005).
  • Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature413(6857), 732–738 (2001).
  • Gitlin L, Barchet W, Gilfillan S et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA103(22), 8459–8464 (2006).
  • Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
  • Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin. Exp. Immunol.141(2), 298–306 (2005).
  • Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun.68(12), 7010–7017 (2000).
  • Gerone PJ, Hill DA, Appell LH, Baron S. Inhibition of respiratory virus infections of mice with aerosols of synthetic double-stranded ribonucleic acid. Infect. Immun.3(2), 323–327 (1971).
  • Singh B, Postic B. Enhanced resistance of mice to virulent Japanese B encephalitis virus following inactivated vaccine and poly I:C. J. Infect. Dis.122(4), 339–342 (1970).
  • Tucker S. Application of a novel oral delivery platform to avian flu vaccination. In: CBI: Vaccine Development Conference. Center for Business Intelligence, PA, USA (2007).
  • Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA96(8), 4512–4517 (1999).
  • Kilhamn J, Jertborn M, Svennerholm AM. Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine. Clin. Diagn. Lab. Immunol.5(2), 247–250 (1998).
  • Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther.6(9), 1574–1583 (1999).
  • Nwanegbo E, Vardas E, Gao W et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol.11(2), 351–357 (2004).
  • Schulick AH, Vassalli G, Dunn PF et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest.99(2), 209–219 (1997).
  • Ophorst OJ, Radosevic K, Havenga MJ et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect. Immun.74(1), 313–320 (2006).
  • Kay MA, Holterman AX, Meuse L et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet.11(2), 191–197 (1995).
  • Kay MA, Meuse L, Gown AM et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Natl Acad. Sci. USA94(9), 4686–4691 (1997).
  • Croyle MA, Chirmule N, Zhang Y, Wilson JM. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol.75(10), 4792–4801 (2001).
  • Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther.8(5), 341–348 (2001).
  • Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature441(7090), 239–243 (2006).
  • Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro.Gene Ther.5(7), 995–1002 (1998).
  • Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, Davidson BL. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo.Gene Ther.5(6), 740–746 (1998).
  • Rahman A, Tsai V, Goudreau A et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol. Ther.3(5 Pt 1), 768–778 (2001).
  • Klonjkowski B, Gilardi-Hebenstreit P, Hadchouel J et al. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo.Hum. Gene Ther.8(17), 2103–2115 (1997).
  • Xiang Z, Li Y, Gao G, Wilson JM, Ertl HC. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J. Immunol.171(8), 4287–4293 (2003).
  • Hodges BL, Taylor KM, Chu Q et al. Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver. Mol. Ther.12(6), 1043–1051 (2005).
  • Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol.77(20), 10780–10789 (2003).
  • Wang Y, Xiang Z, Pasquini S, Ertl HC. Immune response to neonatal genetic immunization. Virology228(2), 278–284 (1997).
  • Kotton CN, Lankowski AJ, Scott N et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine24, 6216 (2006).
  • Harms JS, Splitter GA. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther.6(10), 1291–1297 (1995).
  • Kresge K. A STEP back. In: IAVI Report.11(5), 1–5 (2007).

Websites

  • Duramed. A clinical trial to evaluate the safety, efficacy, and immunogenicity of DR-5001. In: Search from Clinical Trials.Gov (2007) http://clinicaltrials.gov/ct/gui/show/NCT00382408?order=4.
  • Poland G. Vaccines in the military: a department of defense-wide review of vaccine policy and practice. In: Armed Forces Epidemiological Board (1999) www.ha.osd.mil/afeb/reports/vaccines.pdf.
  • CDC case reports MMWR 50(26), 553–555 (2001). www.cdc.gov/mmwR/preview/mmwrhtml/mm5026a1.htm
  • Winkenworder. Adenovirus vaccine fact sheet. (2004). http://www.vaccines.mil/documents/608AdenoFactSheet.pdf.
  • Sun W. Adenovirus vaccine restoration, a clinical perspective. In: Armed Forces Epidemiology Board (Ft. Bragg, NC, 2005–2005/december/
  • Coffey L. Vaccine trials for ‘Boot Camp Crud’ may help 20 Percent of recruits (2006) www.armymedicine.army.mil/news/releases/20061116_adenovirus.cfm?m=11&y=2006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.